Literature DB >> 7849125

Sentinel surveillance of HIV-1 infection in Tamilnadu, India.

S Solomon1, S Anuradha, M Ganapathy.   

Abstract

The objective was to determine the time trends in the prevalence of HIV infection and to evaluate appropriate preventive intervention in different population groups. Sentinel surveillance of HIV-1 infection by anonymous unlinked technique was carried out in Tamilnadu from December 1989 to March 1993. The sentinel population monitored were attendees of STD clinics, blood donors and antenatal mothers. The results of HIV seropositivity were compared for each 6-month period. During the study period there was 10-fold rise of HIV seropositivity among STD patients (1% to 10%), 2-fold rise among antenatal attendees (0.37% to 0.76%), and 3-fold rise in blood donors (0.24% to 0.72%). There was a steady increase in the incidence of HIV infection among those with high risk behaviour (STD attendees) as well as in the general population. This information is of value in planning and evaluation of preventive and control programmes in India.

Entities:  

Keywords:  Asia; Blood Donors; Blood Supply; Demographic Factors; Developing Countries; Diseases; Equipment And Supplies; Examinations And Diagnoses; Hiv Serodiagnosis; Incidence--changes; India; Infections; Laboratory Examinations And Diagnoses; Measurement; Population; Population Characteristics; Pregnant Women; Reproductive Tract Infections; Research Methodology; Research Report; Sexually Transmitted Diseases; Southern Asia

Mesh:

Year:  1994        PMID: 7849125     DOI: 10.1177/095646249400500613

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  2 in total

1.  HIV epidemic in Punjab, India: time trends over a decade.

Authors:  S Sehgal
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

2.  Community Health Centers and Sentinel Surveillance of Human Trafficking in the United States.

Authors:  Michael Gallo; Hannah Thinyane; James Teufel
Journal:  Public Health Rep       Date:  2022 Jul-Aug       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.